MYOK News and Press, MyoKardia Inc. From 01/14/20

The following slide deck was published by MyoKardia, Inc. in conjunction with this Read more ...

SOUTH SAN FRANCISCO, Calif., Jan. 06, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), today announced that Tassos Gianakakos, Chief Executive Officer, will present at the 38 th Annual J.P. Morgan Healthcare Conference on Monday, January 13 th , 2020 at 8:30 a.m. PT (11:30 a.m. ET)...

MyoKardia ( MYOK ) is a clinical-stage biopharma company pioneering a precision medicine approach for the treatment of serious cardiovascular diseases. Precision medicine involves discovering and developing therapies that integrate clinical and molecular information based on the biological bas...

SOUTH SAN FRANCISCO, Calif., Nov. 27, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), today announced that Tassos Gianakakos, Chief Executive Officer, will participate in a fireside chat at the Evercore ISI 2 nd  Annual HealthCONx Conference on Wednesday, December 4 th , 2019...

Image source: The Motley Fool. MyoKardia, Inc.   (NASDAQ: MYOK) Q3 2019 Earnings Call Nov 11, 2019 , 8:30 a.m. ET Operator Continue reading

A 59-subject Phase 2 clinical trial, MAVERICK-HCM , evaluating MyoKardia's (NASDAQ: MYOK ) mavacamten in patients with non-obstructive hypertrophic cardiomyopathy  (HCM) (the walls of the ventricles thicken compromising blood flow) met the primary endpoint of safety at week 16. More...

Mavacamten’s Safety and Efficacy Profile in the PIONEER Study Maintained Through One Year in Open-Label Extension Study of 12 Patients with Symptomatic, Obstructive HCM Evidence Suggests Mavacamten’s Favorable Impact on Cardiac Structure Conference Call To...

Achieved Primary Study Objective of Safety and Tolerability in Patients with Non-obstructive HCM Significant Reductions in Biomarkers of Cardiac Stress Observed in Patients on Treatment vs. Placebo Data Support Advancement of Mavacamten in Non-obstructive HCM; Regulatory Update A...

SOUTH SAN FRANCISCO, Calif., Nov. 06, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), today announced that Tassos Gianakakos, Chief Executive Officer, will participate in a fireside chat at the Credit Suisse 28 th Annual Healthcare Conference on Wednesday, November 13 th , 2019, a...

MyoKardia (NASDAQ: MYOK ): Q3 GAAP EPS of -$3.07 misses by $1.06 . More news on: MyoKardia, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...